Short Interest in Integra LifeSciences Holdings Co. (NASDAQ:IART) Grows By 26.8%

Integra LifeSciences Holdings Co. (NASDAQ:IART - Get Free Report) was the target of a significant growth in short interest during the month of May. As of May 15th, there was short interest totalling 4,830,000 shares, a growth of 26.8% from the April 30th total of 3,810,000 shares. Based on an average daily volume of 1,040,000 shares, the short-interest ratio is currently 4.6 days. Approximately 7.4% of the shares of the company are sold short.

Institutional Trading of Integra LifeSciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in IART. Assenagon Asset Management S.A. raised its stake in Integra LifeSciences by 2,418.7% during the 1st quarter. Assenagon Asset Management S.A. now owns 1,799,944 shares of the life sciences company's stock valued at $39,581,000 after purchasing an additional 1,728,480 shares during the period. Soleus Capital Management L.P. bought a new stake in Integra LifeSciences during the 4th quarter valued at approximately $28,940,000. Paradigm Capital Management Inc. NY raised its stake in Integra LifeSciences by 170.3% during the 4th quarter. Paradigm Capital Management Inc. NY now owns 1,431,100 shares of the life sciences company's stock valued at $32,457,000 after purchasing an additional 901,600 shares during the period. Lord Abbett & CO. LLC raised its stake in Integra LifeSciences by 86.8% during the 4th quarter. Lord Abbett & CO. LLC now owns 1,332,031 shares of the life sciences company's stock valued at $30,210,000 after purchasing an additional 618,773 shares during the period. Finally, Norges Bank bought a new stake in Integra LifeSciences during the 4th quarter valued at approximately $8,967,000. Institutional investors own 84.78% of the company's stock.

Analysts Set New Price Targets

Several brokerages have issued reports on IART. Truist Financial dropped their target price on Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. Argus raised Integra LifeSciences from a "hold" rating to a "buy" rating in a research report on Monday, March 31st. Wells Fargo & Company dropped their target price on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. JPMorgan Chase & Co. dropped their target price on Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating on the stock in a research report on Tuesday, May 6th. Finally, JMP Securities dropped their target price on Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating on the stock in a research report on Friday, May 9th. Four investment analysts have rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, Integra LifeSciences presently has a consensus rating of "Hold" and an average price target of $18.63.

Integra LifeSciences Stock Performance

Shares of NASDAQ IART traded up $0.27 during trading on Friday, hitting $13.56. The company had a trading volume of 1,149,288 shares, compared to its average volume of 1,037,187. The stock has a 50 day simple moving average of $15.17 and a 200 day simple moving average of $20.59. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. Integra LifeSciences has a 12 month low of $11.60 and a 12 month high of $32.66. The firm has a market capitalization of $1.05 billion, a P/E ratio of -150.65, a price-to-earnings-growth ratio of 0.73 and a beta of 1.16.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The life sciences company reported $0.41 EPS for the quarter, missing the consensus estimate of $0.43 by ($0.02). Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The company had revenue of $382.65 million during the quarter, compared to the consensus estimate of $381.17 million. During the same period last year, the business earned $0.55 EPS. The firm's quarterly revenue was up 3.7% compared to the same quarter last year. As a group, analysts anticipate that Integra LifeSciences will post 2.45 earnings per share for the current year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.